Does a late evening meal reduce the risk of hepatocellular carcinoma among patients with chronic hepatitis C?

Hepatology Research

Volumn 38, Issue 9, 2008, Pages 860-868

  Ohfuji, Satoko ^a   Fukushima, Wakaba ^a   Tanaka, Takashi ^b   Habu, Daiki ^a   Takeda, Tadashi ^a   Tamori, Akihiro ^a   Sakaguchi, Hiroki ^a   Seki, Shuichi ^a   Kawada, Norifumi ^a   Nishiguchi, Shuhei ^c   Shiomi, Susumu ^a   Hirota, Yoshio ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Hoai Hospital   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Case control study; Hepatitis C virus; Hepatocellular carcinoma; Late evening meal; Risk factor

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; GLUCOSE; INTERFERON;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CALORIC INTAKE; CANCER PREVENTION; CANCER RISK; CONFOUNDING VARIABLE; CONTROLLED STUDY; DIETARY INTAKE; DISEASE DURATION; DISEASE SEVERITY; FAMILY HISTORY; FEMALE; FREQUENCY ANALYSIS; GLUCOSE BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL SUPPORT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; RISK REDUCTION; THROMBOCYTE COUNT;

EID: 48949086335     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2008.00355.x     Document Type: Article

References (46)

1. Plauth M, Merli M, Kondrop J, Weimann A, Ferenci P, Muller MJ. ESPEN guidelines for nutrition in liver disease and transplantation. Clin Nutr 1997; 16: 43-55.
2. Kondrup J, Muller MJ. Energy and protein requirements of patients with chronic liver disease. J Hepatol 1997; 27: 239-47.
3. Muller MJ, Lautz HU, Plogmann B, Burger M, Korber J, Schmidt FW. Energy expenditure and substrate oxidation in patients with cirrhosis: The impact of cause, clinical staging and nutritional state. Hepatology 1992; 15: 782-94.
4. Alberino F, Gatta A, Amodio P et al. Nutrition and survival in patients with liver cirrhosis. Nutrition 2001; 17: 445-50.
5. Tajika M, Kato M, Mohri H et al. Prognostic value of energy metabolism in patients with viral liver cirrhosis. Nutrition 2002; 18: 229-34.
6. Merli M, Riggio O, Dally L, PINC (Policentrica Italiana Nutrizione Cirrosi). Does malnutrition affect survival in cirrhosis? Hepatology 1996; 23: 1041-6.
7. O'Keefe SJ, El-Zayadi AR, Carraher TE, Davis M, Williams P. Malnutrition and immuno-incompetence in patients with liver disease. Lancet 1980; 20: 615-17.
8. Nakaya Y, Harada N, Kakui S et al. Severe catabolic state after prolonged fasting in cirrhotic patients: Effect of oral branched-chain amino-acid-enriched nutrient mixture. J Gastroenterol 2002; 37: 531-6.
9. Moriwaki H, Tajika M, Miwa Y et al. Nutritional pharmacotherapy of chronic liver disease: From support of liver failure to prevention of liver cancer. J Gastroenterol 2000; 35 (Suppl. 12): 13-17.
10. ASPEN Board of Directors and the Clinical Guidelines Task Force. Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. JPEN 2002; 26: 65SA-8.
11. Okamoto M, Sakaida I, Tsuchiya M, Suzuki C, Okita K. Effect of a late evening snack on the blood glucose level and energy metabolism in patients with liver cirrhosis. Hepatol Res 2003; 27: 45-50.
12. Donaghy A. Issues of malnutrition and bone disease in patients with cirrhosis. J Gastroenterol Hepatol 2002; 17: 462-6.
13. Fukushima H, Miwa Y, Ida E et al. Nocturnal branched-chain amino acid administration improves protein metabolism in patients with liver cirrhosis: Comparison with daytime administration. J Parenter Enteral Nutr 2003; 27: 315-22.
14. Tsuchiya M, Sakaida I, Okamoto M, Okita K. The effect of a late evening snack in patients with liver cirrhosis. Hepatol Res 2005; 31: 95-103.
15. Yamauchi M, Takeda K, Sakamoto K, Ohata M, Toda G. Effect of oral branched chain amino acid supplementation in the late evening on the nutritional state of patients with liver cirrhosis. Hepatol Res 2001; 21: 199-204.
16. Muto Y, Sato S, Watanabe A et al. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 2005; 3: 705-13.
17. Chang WK, Chao YC, Tang HS, Lang HF, Hsu CT. Effect of extra-carbohydrate supplementation in the late evening on energy expenditure and substrate oxidation in patients with liver cirrhosis. J Parenter Enteral Nutr 1997; 21: 96-9.
18. Zillikens MC, Berg JWO, Wattimena JTD, Rietveld T, Swart GR. Nocturnal oral glucose supplementation. J Hepatol 1993; 17: 377-83.
19. Miwa Y, Shiraki M, Kato M etal. Improvement of fuel metabolism by nocturnal energy supplementation in patients with liver cirrhosis. Hepatol Res 2000; 18: 184-9.
20. Nakaya Y, Okita K, Suzuki K et al. BCAA-enriched snack improves nutritional state of cirrhosis. Nutrition 2007; 23: 113-20.
21. Matsui Y, Uhara J, Satoi S et al. Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: A prospective cohort study. J Hepatol 2002; 37: 78-86.
22. Muto Y, Moriwaki H, Ninomiya M et al., for the Hepatoma Prevention Study Group. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Eng J Med 1996; 334: 1561-7.
23. Wada I, Hara T, Kajihara S et al. Population-based study of hepatitis C virus infection and hepatocellular carcinoma in western Japan. Hepatol Res 2002; 23: 18-24.
24. Ohfuji S, Fukushima W, Tanaka T et al. Coffee and reduced risk of hepatocellular carcinoma among chronic hepatitis C patients: A case-control study. Hepatol Res 2006; 36: 201-8.
25. Fukushima W, Tanaka T, Ohfuji S et al. Does alcohol increase the risk of hepatocellular carcinoma among patients with hepatitis C virus infection? Hepatol Res 2006; 34: 141-9.
26. Habu D, Nishiguchi S, Enomoto M et al. Ultrasonographic diagnosis of degree of chronic type C liver disease. Hepatogastroenterology 2005; 52: 1820-4.
27. Kurioka N, Asai H, Harihara S, Yamamoto S. Liver cirrhosis. Kan Tan Sui 1985; 10: 383-9.
28. Ohtake K. Evaluation of criteria on liver cirrhosis used for ultrasonic mass survey. Osaka City Med J 1991; 40: 173-94.
29. Ikeda K, Saitoh S, Kobayashi M et al. Distinction between chronic hepatitis and liver cirrhosis in patients with hepatitis C virus infection. Practical discriminant function using common laboratory data. Hepatol Res 2000; 18: 252-66.
30. Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998; 93: 44-8.
31. Williams ALB, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Gastroenterol 1988; 95: 734-9.
32. The Examination Committee of Criteria for 'Obesity Disease' in Japan, Japan Society for the Study of Obesity. New criteria for 'obesity disease' in Japan. Circ J 2002; 66: 987-92.
33. Sugiyama K, Yu L, Nagasue N. Direct effect of branched-chain amino acids on the growth and metabolism of cultured human hepatocellular carcinoma cells. Nutr Cancer 1998; 31: 62-8.
34. Nishiguchi S, Habu D. Effect of oral supplementation with branched-chain amino acid granules in the early stage of cirrhosis. Hepatol Res 2004; 30 (Suppl.): 36-41.
35. Habu D, Nishiguchi S, Nakatani S et al. Effect of oral supplementation with branched-chain amino acid granules on serum albumin level in the early stage of cirrhosis: A randomized pilot trial. Hepatol Res 2003; 25: 312-18.
36. Muto Y, Sato S, Watanabe A et al. Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol Res 2006; 35: 204-14.
37. Marchesini G, Bianchi G, Rossi B, Brizi M, Melchionda N. Nutritional treatment with branched-chain amino acids in advanced liver cirrhosis. J Gastroenterol 2000; 35 (Suppl. 12): 7-12.
38. Swart GR, Zillikens MC, Vuure JK, Berg JWO. Effect of a late evening meal on nitrogen balance in patients with cirrhosis of the liver. BMJ 1989; 299: 1202-3.
39. WPHG Venne V, Westerterp KR, Hoek B, Swart GR. Energy expenditure and substrate metabolism in patients with cirrhosis of the liver: Effects of the pattern of food intake. Gut 1995; 36: 110-16.
40. Marchesini G, Bianchi G, Merli M et al. for the Italian BCAA Study Group. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: A double-blind, randomized trial. Gastroenterology 2003; 124: 1792-801.
41. Marchesisni G, Dioguardi FS, Bianchi GP et al. and the Italian Multicenter Study Group. Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy: A randomized double-blind casein-controlled trial. J Hepatol 1990; 11: 92-101.
42. The San-In Group of Liver Surgery. Long-term oral administration of branched chain amino acids after curative resection of hepatocellular carcinoma: A prospective randomized trial. Br J Surg 1997; 84: 1525-31.
43. Yoshida T, Muto Y, Moriwaki H, Yamato M. Effect of long-term oral supplementation with branched-chain amino acid granules on the prognosis of liver cirrhosis. Gastroenterol Jpn 1989; 24: 692-8.
44. Corrao G, Torchio P, Zambon A, D'Amicis A, Lepore AR, Orio F, The Provincial Group for The Study of Chronic Liver Disease. Alcohol consumption and micronutrient intake as risk factors for liver cirrhosis: A case-control study. Ann Epidemiol 1998; 8: 154-9.
45. Habu D, Shiomi S, Tamori A et al. Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA 2004; 292: 358-61.
46. Corrao G, Zambon A, Bagnardi V et al. Nutrient intakes, nutritional patterns and the risk of liver cirrhosis: An explorative case-control study. Eur J Epidemiol 2004; 19: 861-9.